145 related articles for article (PubMed ID: 37464089)
1. Contemporary outcomes of high risk relapsed refractory classical hodgkin lymphoma patients-role of maintenance therapy in the real world.
Damlaj M; Tlayjeh M; Damlaj A; Alahmari B; AlSadi H; Ahmed M; AlJubour Z; Alhejazi A; Salama H; Ibrahim A; Al Raizah A; Bakkar M; Ghori A; Al Saleh AS; Alaskar A; Alzahrani M
Bone Marrow Transplant; 2023 Oct; 58(10):1160-1162. PubMed ID: 37464089
[No Abstract] [Full Text] [Related]
2. Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma.
Kallam A; Vose JM
Oncology (Williston Park); 2019 May; 33(5):192-8. PubMed ID: 31095720
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
4. Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.
Kwong YL; Lopes D; Khong PL
Br J Haematol; 2017 Jan; 176(1):131-132. PubMed ID: 26773814
[No Abstract] [Full Text] [Related]
5. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
6. Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
Manson G; Herbaux C; Schiano JM; Casasnovas O; Stamatoullas A; Deau B; Schmitt A; Regny C; Bouabdallah K; Chauchet A; Ghesquieres H; Tempescul A; Dulery R; Nicolas-Virelizier E; Delmer A; Borel C; Dercle L; Brice P; Houot R;
Br J Haematol; 2022 Jul; 198(1):203-206. PubMed ID: 35445392
[No Abstract] [Full Text] [Related]
7. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
[TBL] [Abstract][Full Text] [Related]
8. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study.
Amraee A; Evazi MR; Shakeri M; Roozbeh N; Ghazanfarpour M; Ghorbani M; Ansari J; Darvish L
Clin Transl Oncol; 2019 Aug; 21(8):1093-1103. PubMed ID: 30739242
[TBL] [Abstract][Full Text] [Related]
10. Dave H, Terpilowski M, Mai M, et al. Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. Blood Adv. 2022;6(2):473-485.
Blood Adv; 2024 Feb; 8(3):683-685. PubMed ID: 38286747
[No Abstract] [Full Text] [Related]
11. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
12. Management of Relapsed and Refractory Hodgkin Lymphoma in 2018.
Rutherford SC; Leonard JP
JAMA Oncol; 2018 Aug; 4(8):1120-1121. PubMed ID: 30003234
[No Abstract] [Full Text] [Related]
13. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016.
Fosså A; Smeland K; Fagerli UM; Galleberg RB; Bersvendsen HS; Holte H
Acta Oncol; 2020 Jan; 59(1):101-105. PubMed ID: 31429371
[No Abstract] [Full Text] [Related]
15. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.
Zhang XY; Collins GP
Curr Oncol Rep; 2022 Nov; 24(11):1477-1488. PubMed ID: 35696020
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab activity in relapsed Hodgkin's lymphoma.
Das M
Lancet Oncol; 2017 Apr; 18(4):e205. PubMed ID: 28318993
[No Abstract] [Full Text] [Related]
18. The efficacy and safety of BV-ICE salvage therapy for relapsed/refractory Hodgkin lymphoma. A single centre.
El Cheikh J; Amhaz G; Zahreddine A; Dalle IA; Bazarbachi A
Curr Res Transl Med; 2022 Jul; 70(3):103339. PubMed ID: 35339033
[No Abstract] [Full Text] [Related]
19. Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies.
Kim DH; Vega F
Blood; 2022 Feb; 139(6):951. PubMed ID: 35142847
[No Abstract] [Full Text] [Related]
20. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
